Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Swedish Orphan Biovitrum AB (publ)

Revenue

Target Prices

# of Analysts

Consensus Recommendation

EBITDA

EBIT

Free Cash Flow

FFO / Share

AFFO / Share

NAV / Share

Book Value / Share

CapEx

Estimates	Dec '22 (A)	Dec '23 (A)	Dec '24 (E)
Mean	SEK 18,363.41	SEK 21,967.7	SEK 24,883.21
Median	SEK 18,399.8	SEK 22,104.66	SEK 24,859
Actual	SEK 18,790	SEK 22,123	—
High	SEK 18,779.5	SEK 22,275.93	SEK 26,048
Low	SEK 17,998.92	SEK 20,975	SEK 24,011.5
Standard Deviation	SEK 226.69	SEK 352.61	SEK 502.98
# of Estimates	10	11	11

Swedish Orphan Biovitrum AB (publ)

Long Term Revisions Restricted